Objectives-To determine the prevalence and clinical associations of autoantibodies to myeloperoxidase (MPO) in an unselected series of well-characterised out-
Vasculitis is a characteristic pathological feature of the extra-articular manifestations of RA although systemic and renal vasculitis are rare. Because of the known clinical association of vasculitis with RA, ANCA have been sought in sera from these patients. However, their prevalence and clinical significance remain unclear with conflicting results reported.5 [7] [8] [9] [10] Many of these differences may be explained by the different methodologies used to characterise these autoantibodies, the small patient numbers and in the selection of patients.
In the largest study of ANCA in RA,5 it was found that p-ANCA were present in only 2-8% of 214 Diagnoses were based on clinical findings, lung function tests, radiographs and computed tomographic scans in all patients and lung biopsy in two. In all cases the lung disease was felt to be associated with the RA.
Disease activity in the patients with rheumatoid arthritis was assessed by comparing tender joint count, ESR, haemoglobin, and a global clinical impression of disease activity (disease activity index, DAI) which was graded 0-2 where 0 represents inactive disease with symptoms, if any, due to degenerative or mechanical factors and 2 represents highly active disease.
Patients with vasculitis Twenty nine patients with rapidly progressive renal failure associated with systemic vasculitis were studied. All patients had a renal biopsy which in each case showed pauci-immune focal and segmental glomerulonephritis compatible with a diagnosis of systemic vasculitis. At diagnosis, sera from all patients gave a p-ANCA staining pattern on ethanol-fixed neutrophils.
Normnal subjects
Sera from 50 consecutive normal healthy blood donors, obtained from the Blood Transfusion Unit, were studied as normal controls.
Methods
Detection ofIgM and IgG antibodies to MPO MPO was purified from a primary granule extract of human neutrophils.20 21 The class of anti-MPO antibodies present in sera was measured using a modification of an ELISA previously established in this laboratory.6
Briefly, purified MPO was coated on to ELISA plates at a concentration of 1 ug/ml in sodium bicarbonate buffer (0-1 M, pH 9 6) for two hours at room temperature. Uncoated wells were also included to control for background binding of sera. All subsequent incubations were for one hour at 37°C. Sera were diluted 1/100 in PBS containing 01-/% Tween and 2% bovine serum albumin (PBT) for use. Binding of antibodies to MPO was detected using alkaline phosphatase conjugated goat antihuman IgM or IgG (Sigma Chemical) diluted 1/5000 in PBT with p-nitrophenol phosphate (1 mg/ml in sodium bicarbonate buffer). 
Patient 2 first had detectable anti-MPO antibodies in her serum at the time she had a chronic staphylococcal infection of a total knee replacement. There was no evidence of vasculitis.
Three patients (5,6,11) had only IgG anti-MPO antibodies and a significant titre of antithyroid microsomal antibodies. None of these patients had extra-articular rheumatoid disease: one had symptomatic thyroid disease and had had a thyroidectomy.
Patients 4, 8 and 10 all had long-standing (> 10 years) seropositive disease with no extraarticular features. Patient 12 had a three year history of RA with no extra-articular disease.
Discussion
In this study anti-MPO antibodies were found in sera from approximately 12% of a group of unselected outpatients with rheumatoid arthritis with varying levels of disease activity. This figure is similar to that reported in several other studies.7 8 We could not confirm an association between the presence of cutaneous vasculitis and anti-MPO antibodies. None of the patients we studied, however, had systemic vasculitis. We confirmed that 83% of p-ANCA containing sera from patients with systemic vasculitis had specificity for MPO.
Many of the differences between the studies of ANCA in RA may be explained by the different methods used to define antigen specificity. For example, the interpretation of a p-ANCA staining pattern may be complicated by the presence of anti-nuclear antibodies in the same serum, since antibodies of these specificities can cause similar or overlapping staining patterns. Cross reactivity with antithyroid microsomal antibodies, specific for thyroperoxidase (TPO), may result in a positive test for anti-MPO antibodies in ELISA. In a small study in this laboratory (data not shown) it was found that 2/10 sera from patients with anti-TPO antibodies confirmed by specific ELISA (Cambridge Life Sciences) reacted with MPO in ELISA and gave a perinuclear staining pattern on ethanol-fixed human neutrophils. Conversely, none of 12 sera from patients with vasculitis whose sera contained anti-MPO antibodies reacted with TPO. Sera from three patients in this study contained significant levels of anti-TPO antibodies, which may have caused the positive result in the MPO ELISA. It is thus important to recognise the presence of thyroid microsomal antibodies as a possible cause of an unexpectedly positive anti-MPO or ANCA test in some patients.
We noted an unexpected association between rheumatoid lung disease and anti-MPO antibodies. The association of acute pulmonary haemorrhage, lung vasculitis and presence of ANCA is well known. ANCA have also been described in idiopathic pulmonary fibrosis24 and in these cases an occult pulmonary vasculitis was suggested. The presence of anti-MPO antibodies in sera from patients with RA-associated pulmonary fibrosis may imply that a sub-clinical pulmonary vasculitis may also lead to fibrosis in these patients. Further studies of anti-MPO antibodies in these and other patients with rheumatoid lung disease are being carried out in this department.
In this study we found 90%/ of sera from patients with vasculitis contained IgG4 anti-MPO antibodies, compared with only 18% of positive sera from RA patients where antibodies of the IgGI and 3 subclasses predominated. Of the two patients with rheumatoid arthritis who had IgG4 anti-MPO antibodies one had long standing active disease and cutaneous vasculitis. Studies of stored sera showed he had had anti-MPO antibodies in his sera for 15 years. Anti-MPO antibodies in the other patient with IgG4 anti-MPO antibodies had been present for the two years for which sera were available. Stored sera were available from four other anti-MPO antibody positive patients with rheumatoid arthritis. Anti-MPO antibodies had been present in all these sera for more than six years, but none of these antibodies was of the IgG4 subclass.
Antibodies of the IgG4 sub-class are closely associated with eosinophilia, raised levels of IgE and hypersensitivity (which is often a feature of some forms of vasculitis),25 and also linked with prolonged exposure to antigen.26 The relative paucity of IgG4 anti-MPO antibodies in patients with RA compared with vasculitis patients may reflect differences in the relative length of exposure to the antigenic stimulus and the balance between T cell regulatory factors at the site of antigenic stimulus. In vasculitis, there is some evidence for a long interval between the appearance of ANCA and clinical disease. In contrast, anti-MPO antibodies present in sera from the three patients with rheumatoid lung disease reported here were of IgG1, and 3 subclasses and anti-MPO antibodies were first detected in the serum within six months of diagnosis of lung disease. The close association of systemic vasculitis with infections has suggested that the development of ANCA in this situation may result from cross reaction with infecting organisms. The likely site of infection, and of initiation of the antibody response, is the respiratory tract. In rheumatoid arthritis, the appearance of anti-MPO antibodies and antibodies to other neutrophil enzymes may be the consequence of neutrophil destruction within the rheumatoid joint, the primary site of tissue destruction, possibly due to the presence of increased lymphocyte and accessory cell traffic. The balance of T cell regulatory factors at the site of antigen presentation-possibly the joint in RA and the lung in systemic vasculitis-may help to explain the difference in IgG subclasses in the two conditions. Solid phase assays for the detection of ANCA are now widely available and increasingly used by rheumatologists to investigate patients with autoimmune rheumatic disease as well as systemic vasculitis.
More information about the incidence and clinical correlates of autoantibodies reacting specifically with neutrophil granule proteins is needed to allow these assay results to be interpreted. The availability of patients in the Middlesex Hospital RA Prospective Study has enabled us to investigate in detail the circulating autoantibody response to one of these granule proteins in a well characterised group of patients with RA.
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